Enveric Biosciences, Inc. Income Statement
ENVB|3 years of annual SEC 10-K data (FY2017-FY2019)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Enveric Biosciences, Inc. reported $43M in revenue and $17M in net loss for FY2019. Revenue has grown at a 9.1% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 | FY2017 |
|---|---|---|---|
| Revenue | $43.0M | $48.6M | $36.1M |
| Cost of Revenue | $34.0M | $38.4M | $29.2M |
| Gross Profit | $9.0M | $10.2M | $6.9M |
| SG&A Expense | $10.8M | $18.5M | $9.4M |
| Operating Income | -$7.1M | -$10.9M | -$5.4M |
| Interest Expense | $729.9K | $575.0K | $751.1K |
| Income Tax | $6.3M | -$2.4M | -$3.7M |
| Net Income | -$16.9M | -$9.1M | -$2.8M |
| EPS (Basic) | -$20.47 | -$0.75 | -$0.21 |
| EPS (Diluted) | -$20.47 | -$0.75 | -$0.21 |
| Shares Outstanding | 1.7M | 18.2M | 13.9M |
| Gross Margin | 20.9% | 21.1% | 19.2% |
| Operating Margin | -16.6% | -22.4% | -14.9% |
| Profit Margin | -39.3% | -18.7% | -7.7% |